Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$7.00 and last traded at C$7.00, with a volume of 144 shares traded. The stock had previously closed at C$7.09.
Fennec Pharmaceuticals Price Performance
The company has a 50-day moving average of C$7.95 and a 200 day moving average of C$10.20. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The stock has a market capitalization of C$191.52 million, a PE ratio of 70.90 and a beta of 0.26.
Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). The business had revenue of C$9.94 million for the quarter, compared to analysts’ expectations of C$18.67 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. Sell-side analysts predict that Fennec Pharmaceuticals Inc. will post 0.6037575 EPS for the current year.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Recommended Stories
- Five stocks we like better than Fennec Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- The Average 401k Balance by Age Explained
- How to Read Stock Charts for Beginners
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the FTSE 100 index?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.